CSL Behring Our Company Coronavirus Information CSL Behring Coronavirus Information We are committed to continuing to provide our medicines to patients around the world, while pursuing COVID-19 treatments through a variety of collaborations. Helpful Stories for Patients During the COVID-19 Crisis Messages of encouragement, tips for staying healthy and podcast insights into what CSL Behring is doing to help battle the pandemic. Read More News Releases & Updates CSL Behring’s Global Role in Battling COVID-19 17 September 2021: Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19. Read Fact Sheet COVID-19 Update 2 JUNE 2021: CSL continues to provide medicines to patients around the world. Read Company Update CoVIg-19 Plasma Alliance Announces Topline Results from Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine 2 APRIL 2021: Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial did not meet its endpoints to show efficacy in adults hospitalized with COVID-19. Read Release CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne 8 NOVEMBER 2020: CSL has separate contracts with AstraZeneca and the Australian Government to manufacture doses of the AZD1222 vaccine candidate, with first doses planned for release in the first half of 2021, pending the outcome of clinical trials and regulatory approval. Read Release on CSL.com First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine 8 OCTOBER 2020: The anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19. Read Release In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress 6 JULY 2020: Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia Read Release Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation 26 MAY 2020: “The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies Read Release CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration 7 MAY 2020: Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach Read Release CSL Behring Australia Commences Development of Treatment for Serious Cases of COVID-19 6 MAY 2020: Plasma-derived therapeutic with potential to treat serious complications of COVID-19 Read Release CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic 8 APRIL 2020: COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer. Read Release Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy 6 APRIL 2020: Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19. Read Release Contact CSL, All Rights Reserved © 2021 Terms of Use Cookie Policy Privacy Policy Accessibility Statement Patents Sitemap By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies